Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CD70.CAR NK cells + Rimiducid |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CD70.CAR NK cells | CD70 CAR NK cells|CD70.CAR NK-cells | CD70 Immune Cell Therapy 11 | Limited information is currently available on CD70.CAR NK cells, putative cord blood-derived natural killer (NK) cells expressing a chimeric antigen receptor (CAR) targeting CD70 (Oct 2025). | |
| Rimiducid | AP1903|AP-1903|AP 1903 | Rimiducid (AP1903) is a small molecule that selectively binds to mutant FKBP12 and induces dimerization and downstream signaling, which can be used to activate a safety switch in transplanted cells to potentially induce apoptosis and prevent graft-versus-host disease (PMID: 9724721, PMID: 22047558, PMID: 28697888). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07164469 | Phase II | CD70.CAR NK cells + Rimiducid Cyclophosphamide + Fludarabine | Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma | Not yet recruiting | USA | 0 |